Advertisement
News
Advertisement

DART sees success with Duchenne biomarker

Wed, 10/10/2012 - 12:00am
Mass High Tech: The Journal of New England Technology

DART Therapeutics LLC, a biotech focused on finding therapies for Duchenne Muscular Dystrophy (DMD), a progressive and fatal neuromuscular disease for which there is no current treatment, has completed tests on a new biomarker intended to speed drug development by cutting the number of patients needed for new drug trials by half.

Advertisement

Share this Story

X
You may login with either your assigned username or your e-mail address.
The password field is case sensitive.
Loading